自然に発生するT細胞変異は,人工T細胞療法を強化する
Julie Garcia1,2,3, Jay Daniels1,4,5,3, Yujin Lee4,5
1Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.
Nature
|February 7, 2024
まとめ
科学者はT細胞がんから CARD11-PIK3R3という 遺伝子の融合を発見し T細胞治療の持続性と抗腫瘍効果を高めました この発見は自然に発生する変異を活用して 癌治療を改善する有望な戦略を示しています
科学分野:
- 免疫学
- 腫瘍学
- 分子生物学
背景:
- アドプティブT細胞療法はがん治療に有望だが,T細胞の持続性と機能の低下によって制限されている.
- 癌性T細胞は 困難な環境下での生存を向上させる変異を起こし 治療改善の潜在的洞察力を提供します
研究 の 目的:
- 治療性T細胞機能を高める可能性について,T細胞腫瘍の変異を体系的にスクリーニングする.
- 採用型T細胞療法におけるT細胞の持続性と抗腫瘍効果を改善できる特定の変異を特定し,特徴づけること.
主な方法:
- T細胞のシグナル伝達,シトカインの産生,およびin vivoの持続性への影響を評価するために,T細胞の腫瘍から71の変異をスクリーニングした.
- 皮膚T細胞リンパ腫のCD4+モデルでCARD11-PIK3R3遺伝子の融合を特定し,検証した.
- CARD11- PIK3R3発現するT細胞の抗腫瘍効果を免疫療法耐性モデルで評価した.
主要な成果:
- CARD11- PIK3R3遺伝子の融合が特定され,CARD11- BCL10- MALT1複合体のシグナル伝達を増強することが示されました.
- CARD11- PIK3R3は,抗原に依存した方法で,複数の耐火性がんモデルにおける治療性T細胞の抗腫瘍効果を著しく高めました.
- CARD11- PIK3R3を発現するT細胞は,悪性変異なし,最大418日間,in vivoで安全に持続することが示された.
結論:
- CARD11-PIK3R3のような自然に発生する突然変異を活用することは,採用型T細胞療法を強化するための実行可能な戦略です.
- このアプローチはT細胞生物学の極限を探求し,がん治療を改善するための進化的解決策の適用を可能にします.
- CARD11-PIK3R3融合は,T細胞ベースのがん免疫療法の安全性と有効性を向上させる有望な候補である.
関連する概念動画
Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
T Cell Activation and Clonal Selection
735
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
735
Mismatch Repair
4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K
Cell-mediated Immune Responses
68.3K
Overview
68.3K
Cytotoxic T Cells-mediated Immune Response
917
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
917
Cancers Originate from Somatic Mutations in a Single Cell
11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K


